Prilenia Therapeutics Collaborates with Ferrer to Co-Develop and Commercialize Pridopidine for Indications Beyond Huntington’s Disease (HD)
Shots:
- Prilenia & Ferrer have entered into a collaboration & license agreement to co-develop & commercialize pridopidine for indications beyond HD in Europe & select markets, with Prilenia retaining rights in major markets incl. North America, Japan, & APAC
- As per the deal, Prilenia will receive ~$90.8M upfront, ~$51.1M in near-term development, regulatory, & commercial milestones, plus additional milestone payments, making an aggregate of ~$568M & is eligible to receive net sales-based tiered double-digit royalties
- Additionally, Prilenia & Ferrer plan to initiate a P-III trial of pridopidine in ALS to confirm P-II (HEALEY ALS) trial results, with CHMP opinion for HD expected in H2’25. Discussions with the FDA are ongoing to determine next steps for HD in the US
Ref: BussinessWire | Image: Prilenia & Ferrer
Related News:- Orion Pharma Collaborates with Criceto for Aporon to Treat OFF Episodes in Parkinson’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information, connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
